Lilly Plans to Offer 8 New Drugs

Here are the eight Eli Lilly & Co. drugs the company hopes to launch by the end of 2004, pending regulatory approval, with expected launch dates:

* Forteo: A bone-building agent to reverse osteoporosis, 2002.

* Cialis: Developed with Bothell, Wash.-based Icos Corp. to treat male erectile dysfunction, 2002.

* Atomexetine: A non-stimulant to treat attention deficit disorder in children, late 2002.

* Duloxetine: For depression, late 2002.

* Olanzipine and Fluoxetine combination: For treatment-resistant depression and psychotic depression. Submission for regulatory approval expected next year.

* Alimta: For treatment of mesothelioma, a rare lung cancer linked to asbestos exposure. Submission for approval expected mid-2002.

* Duloxetine: For urinary incontinence. Submission for approval expected late 2002.

* PKC beta inhibitor: For treatment of diabetic macular edema and diabetic retinopathy, the leading cause of blindness in people younger than 65. Submission for approval expected in 2003.